Profound Medical's TULSA Procedure Matches Robotic Prostatectomy in Landmark CAPTAIN Trial
Profound Medical Corp. announced that the CAPTAIN trial compared MRI-guided TULSA Procedure with robotic prostatectomy for prostate cancer. The trial showed faster recovery for TULSA patients. Dr. Pejman Ghanouni received an award for presenting the data at the 2025 RSNA Annual Meeting. The news was generated by AI and published by Profound Medical Corp. via GlobeNewswire.
Profound Medical Corp. announced that Dr. Pejman Ghanouni of Stanford University School of Medicine received the Cum Laude award at the 2025 Radiological Society of North America (RSNA) Annual Meeting for presenting perioperative data from the CAPTAIN randomized controlled trial. The CAPTAIN trial is the first randomized controlled study to compare MRI-guided transurethral ultrasound ablation (TULSA) with standard robotic radical prostatectomy for prostate cancer and successfully recruited to its target. The results presented indicated that patients treated with the TULSA Procedure experienced significantly faster post-treatment recovery compared to those who underwent robotic radical prostatectomy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profound Medical Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597368-en) on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
